Tenaya Therapeutics Stock In The News
| TNYA Stock | USD 3.57 0.28 8.51% |
Our overall analysis of Tenaya Therapeutics' news coverage and content from conventional and social sources shows investors' strong bullish mood towards Tenaya Therapeutics. The specific impact of Tenaya Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Tenaya Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Tenaya Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Tenaya Therapeutics Backtesting and Tenaya Therapeutics Hype Analysis. For information on how to trade Tenaya Stock refer to our How to Trade Tenaya Stock guide.
Tenaya |
Tenaya Therapeutics Today Top News and Investor Outlook
Tenaya Therapeutics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Tenaya and other traded companies coverage with news coverage. We help investors stay connected with Tenaya headlines for the 30th of November to make an informed investment decision based on correlating the impacts of news items on Tenaya Stock performance. Please note that trading solely based on the Tenaya Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Tenaya Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Tenaya earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Tenaya Therapeutics that are available to investors today. That information is available publicly through Tenaya media outlets and privately through word of mouth or via Tenaya internal channels. However, regardless of the origin, that massive amount of Tenaya data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Tenaya Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Tenaya Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Tenaya Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Tenaya Therapeutics alpha.
Tenaya Largest EPS Surprises
Earnings surprises can significantly impact Tenaya Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-09 | 2024-06-30 | -0.39 | -0.34 | 0.05 | 12 | ||
2023-08-09 | 2023-06-30 | -0.5 | -0.45 | 0.05 | 10 | ||
2024-11-07 | 2024-09-30 | -0.3671 | -0.3 | 0.0671 | 18 | ||
2023-11-08 | 2023-09-30 | -0.47 | -0.39 | 0.08 | 17 | ||
2022-11-10 | 2022-09-30 | -0.64 | -0.74 | -0.1 | 15 | ||
2022-05-11 | 2022-03-31 | -0.64 | -0.75 | -0.11 | 17 |
Tenaya Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Tenaya Therapeutics Stock. Current markets are slightly bearish. About 51% of major world exchanges and indexes are down. See today's market update for more information.
26th of November 2024
Tenaya shares retain Buy rating, price target on trial update at investing.com
26th of November 2024
ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference at gurufocus.com
26th of November 2024
Ocular Therapeutix to Participate in December Investor and Scientific Conferences at globenewswire.com
25th of November 2024
Tenaya Therapeutics Buy Rating Reiterated at HC Wainwright at thelincolnianonline.com
22nd of November 2024
Eyenovia Provides Update on Restructuring Efforts at gurufocus.com
22nd of November 2024
Alpha Tau Medical Receives Buy Rating from HC Wainwright - MarketBeat at news.google.com
20th of November 2024
RANI Third Quarter Update at finance.yahoo.com
19th of November 2024
Akero Therapeutics chief development officer sells 251,274 in stock - Investing.com at news.google.com
18th of November 2024
Disposition of 2258 shares by Chihiro Saito of Tenaya Therapeutics at 2.12 subject to Rule... at MacroaxisInsider
18th of November 2024
Acquisition by Misbah Tahir of 66667 shares of IGM Biosciences subject to Rule 16b-3 at MacroaxisInsider
15th of November 2024
Wall Street Analysts Think Monte Rosa Therapeutics Could Surge 100.47 percent Read This Be... at zacks.com
15th of November 2024
Redmile Group, LLC Adjusts Stake in Stoke Therapeutics Inc - GuruFocus.com at news.google.com
15th of November 2024
ARMISTICE CAPITAL, LLC Expands Stake in Vincerx Pharma Inc at gurufocus.com
15th of November 2024
Ocular Therapeutix Inc Q3 2024 Earnings Call Highlights Strong Financial Position and ... at finance.yahoo.com
14th of November 2024
RTW INVESTMENTS, LP Expands Stake in Akero Therapeutics Inc at gurufocus.com
14th of November 2024
After Plunging -15.92 percent in 4 Weeks, Heres Why the Trend Might Reverse for Gossamer B... at zacks.com
14th of November 2024
ARMISTICE CAPITAL, LLC Acquires New Stake in Rani Therapeutics H - GuruFocus.com at news.google.com
13th of November 2024
Were A Little Worried About Biomea Fusions Cash Burn Rate - Yahoo Finance at news.google.com
13th of November 2024
Ocular Therapeutix Q3 2024 Earnings Preview at seekingalpha.com
12th of November 2024
IGM Biosciences Insiders Who Sold Avert US165m Market Cap Dip at simplywall.st
12th of November 2024
News Flash Analysts Just Made A Sizeable Upgrade To Their Monte Rosa Therapeutics, Inc. Fo... at simplywall.st
12th of November 2024
Vincerx Pharma GAAP EPS of -0.17 at seekingalpha.com
12th of November 2024
Corvus Pharmaceuticals Inc Reports Q3 2024 GAAP EPS of -0.60 and Net Loss of 40.2 Million at gurufocus.com
12th of November 2024
Eyenovia GAAP EPS of -0.11 in-line, revenue of 1.62M beats by 1.51M at seekingalpha.com
11th of November 2024
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635 at businesswire.com
11th of November 2024
Inozyme Pharma to Present at Upcoming Investor Conferences at globenewswire.com
7th of November 2024
Bicycle Therapeutics Looking Again At An Intriguing Developmental Concern - Seeking Alpha at news.google.com
7th of November 2024
Acquisition by Ticho Barry of 10000 shares of Stoke Therapeutics at 0.6 subject to Rule 16... at MacroaxisInsider
5th of November 2024
Stoke Therapeutics, Inc. Reports Q3 Loss, Tops Revenue Estimates at zacks.com
1st of November 2024
Heres Why Were Watching Tenaya Therapeutics Cash Burn Situation at finance.yahoo.com
31st of October 2024
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Res... at businesswire.com
31st of October 2024
Will Monte Rosa continue to dip in December at Macroaxis
28th of October 2024
Monte Rosa jumps on 150M license deal with Novartis at seekingalpha.com
23rd of October 2024
Bicycle Therapeutics plc Announces Positive Human Imaging Data at EANM 2024 Congress and R... at thelincolnianonline.com
21st of October 2024
Scotiabank says its 3 biotech top pick stocks have more than 100 percent upside potential at cnbc.com
18th of October 2024
Acquisition by Burroughs Amy L. of 34000 shares of Tenaya Therapeutics at 2.04 subject to ... at Burroughs Amy L.
18th of October 2024
Disposition of 635 shares by Cheng Andrew of Akero Therapeutics at 21.1 subject to Rule 16... at MacroaxisInsider
17th of October 2024
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the ... at finance.yahoo.com
16th of October 2024
Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at theAmerican Academy... at finance.yahoo.com
15th of October 2024
Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 430 pm ET ... at globenewswire.com
10th of October 2024
Tenaya Therapeutics, Inc. Given Consensus Rating of Buy by Analysts at thelincolnianonline.com
10th of October 2024
What Makes Vincerx Pharma a New Buy Stock at zacks.com
10th of October 2024
Alpha Tau Treats First Patient with Recurrent Lung Cancer at globenewswire.com
7th of October 2024
Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation... at finance.yahoo.com
7th of October 2024
Trading With Integrated Risk Controls - Stock Traders Daily at news.google.com
2nd of October 2024
Stoke therapeutics executive sells 120k in stock at investing.com
1st of October 2024
IGM Biosciences downgraded to Hold, stock falls at seekingalpha.com
30th of September 2024
Gossamer Bio, Inc. Short Interest Down 5.8 percent in September - MarketBeat at news.google.com
30th of September 2024
Eyenovia Announces Share Offering and Warrant Sale for Growth - TipRanks at news.google.com
26th of September 2024
Acquisition by Column Group Iii Gp, Lp of 2222222 shares of Tenaya Therapeutics at 4.5 sub... at Column Group Iii Gp, Lp
24th of September 2024
ALXO stock touches 52-week low at 1.87 amid market challenges - Investing.com at news.google.com
24th of September 2024
Samlyn Capital LLC Has 14.94 Million Stock Position in Inozyme Pharma, Inc. - MarketBeat at news.google.com
18th of September 2024
IGM Biosciences, Inc. CEO Fred Schwarzer Sells 3,946 Shares at thelincolnianonline.com
6th of July 2023
GenScript Doubles cGMP sgRNA and Non-Viral DNA Payload Manufacturing Capacity - Yahoo Fina... at news.google.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Tenaya Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Tenaya Therapeutics' short interest history, or implied volatility extrapolated from Tenaya Therapeutics options trading.
Check out Tenaya Therapeutics Backtesting and Tenaya Therapeutics Hype Analysis. For information on how to trade Tenaya Stock refer to our How to Trade Tenaya Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tenaya Therapeutics. If investors know Tenaya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tenaya Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.44) | Return On Assets (0.46) | Return On Equity (0.84) |
The market value of Tenaya Therapeutics is measured differently than its book value, which is the value of Tenaya that is recorded on the company's balance sheet. Investors also form their own opinion of Tenaya Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Tenaya Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tenaya Therapeutics' market value can be influenced by many factors that don't directly affect Tenaya Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tenaya Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tenaya Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tenaya Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.